Predicting response to new drugs in AML from simulation modelling: Value of the BEAT AML project as a validation resource

Leuk Res. 2019 May:80:43-44. doi: 10.1016/j.leukres.2019.02.006. Epub 2019 Feb 22.

Authors

Brooks Benard¹, Daniel Thomas²

Affiliations

¹ Department of Medicine, Division of Hematology, Stanford Cancer Institute, Institute of Stem Cell and Regenerative Medicine, Stanford University School of Medicine, United States.
² Department of Medicine, Division of Hematology, Stanford Cancer Institute, Institute of Stem Cell and Regenerative Medicine, Stanford University School of Medicine, United States. Electronic address: dthomas3@stanford.edu.

PMID: 30827724
DOI: 10.1016/j.leukres.2019.02.006

No abstract available

Publication types

Editorial

MeSH terms

Humans
Leukemia, Myeloid, Acute*

Grants and funding

T32 CA009302/CA/NCI NIH HHS/United States